beta
Trial Radar AI
Clinical Trial NCT06193083 (DEPAL) for Deprescribing, Palliative Care, Oncology is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

DEprescribing: Perceptions of PAtients Living With Advanced Cancer (DEPAL) 325 Observational

Recruiting
Clinical Trial NCT06193083 (DEPAL) is an observational study for Deprescribing, Palliative Care, Oncology that is recruiting. It started on 28 February 2024 with plans to enroll 325 participants. Led by Nantes University Hospital, it is expected to complete by 29 December 2026. The latest data from ClinicalTrials.gov was last updated on 11 February 2026.
Brief Summary
Polymedication in palliative oncology care is a real public health problem. This phenomenon has been shown to increase the risk of iatrogenesis, reduce patients' quality of life and increase healthcare costs. For many years, health policies have been developed in geriatrics to reduce polymedication through deprescription tools.

Recently, palliative care initiatives have been introduced, but without having studied th...

Show More
Official Title

DEprescribing: Perceptions of PAtients Living With Advanced Cancer. A Multicentre, Prospective Mixed Observational Study

Conditions
DeprescribingPalliative CareOncology
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • DEPAL
  • RC23_0563
NCT ID Number
NCT06193083
Start Date (Actual)
2024-02-28
Last Update Posted
2026-02-11
Completion Date (Estimated)
2026-12-29
Enrollment (Estimated)
325
Study Type
Observational
Status
Recruiting
Keywords
Deprescribing
Palliative care
Oncology
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Qualitative study
The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period).
Semi-directed individual interviews
Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
Quantitative study
Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administere...Show More
The self-administered questionnaires, rPATD and BMQ
rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing. This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal). Following the analysis o...Show More
The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)
FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf ) Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy : Functional literacy: basic reading and writing skills sufficient to function e...Show More
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
To study patients' perceptions of deprescribing in palliative cancer care.
To describe, understand and explain patients' attitudes and beliefs concerning deprescribing by means of individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis) and secondly using the rPATD questionnaire (questionnaire for assessing patients' perceptions of their treatments and deprescribing), which can be adapted following analysis of qualitative data. rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing. This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale
at study inclusion
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
To investigate factors that may influence patients' attitudes and beliefs regarding de-prescribing.
Influence of gender, age, level of education, type of cancer, number of metastatic sites, Performans status score, presence of systemic cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, etc.), follow-up by a palliative care team, and other factors. ), follow-up by a palliative care team, patient's place of care, persons in charge of treatment, number of medications, number of potentially inappropriate medications (PIMs), prognosis assessed by the referring physician, patient's level of education and beliefs about treatments in general (BMQ questionnaire) on scores from the rPATD questionnaire.
at study inclusion
To evaluate the psychometric properties of the rPATD in this population.
Description of rPATD validation data in our population: validation of questionnaire structure, measurement of score reliability, concurrent validation with the BMQ questionnaire. BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication . A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.
at study inclusion
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Patient over 18 years of age
  • Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)
  • Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)
  • Hospitalized or in consultation
  • With at least one PIMs (identified using STOPPfrail 2)
  • Patient not having expressed opposition to participating in the study after receiving information from the physician.

For qualitative study patients :

- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.

  • Minor
  • Major under guardianship, protected person
  • Patient unable to speak or write French
  • Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.
Nantes University Hospital logoNantes University Hospital
  • Fondation de France logoFondation de France
  • Nantes University logoNantes University
Study Central Contact
Contact: Adrien EVIN, MCU-PH, +33253482736, [email protected]
8 Study Locations in 1 Countries
CHD Vendée, La Roche-sur-Yon, 85000, France
Caroline HENNION, PH, Contact, 0251446161, [email protected]
Not yet recruiting
Hospices Civils de Lyon, Lyon, France
Guillaume ECONOMOS, Contact, 04 78 86 10 99, [email protected]
Guillaume ECONOMOS, MD, Principal Investigator
Not yet recruiting
CHU de Nantes, Nantes, 44093, France
Adrien EVIN, MCU-PH, Contact, +33253482736, [email protected]
Adrien EVIN, MCU-PH, Principal Investigator
Elvire PONS-TOSTIVIN, MCU-PH, Sub-Investigator
Yann TOUCHEFEU, PU-PH, Sub-Investigator
André COLPAERT, PH, Sub-Investigator
Gaëlle QUEREUX BAUMGARTNER, MCU-PH, Sub-Investigator
Recruiting
USP - Maison de Nicodème, Nantes, France
Benjamin CHARTIER, Contact, 02 28 24 24 65, [email protected]
Benjamin CHARTIER, MD, Principal Investigator
Not yet recruiting
Hôpital Institut CURIE, Paris, 75005, France
Stéphanie TRAGER, Contact, +33156245500, [email protected]
Stéphanie Träger, Principal Investigator
Not yet recruiting
Institut de Cancérologie de l'Ouest, Saint-Herblain, 44800, France
Véronique BARBAROT, Contact, 0240679900, [email protected]
BARBAROT Véronique, Principal Investigator
Not yet recruiting
CH ST Nazaire, Saint-Nazaire, 44600, France
Virginie DESSUS-CHEVREL, Contact, 0272278000, [email protected]
Virginie DESSUS-CHEVREL, PH, Principal Investigator
Not yet recruiting
CHRU Tours, Tours, France
François CHAUMIER, Contact, 02 47 47 70 30, [email protected]
Not yet recruiting